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Abstract
After the hope and controversy brought by embryonic stem cells two decades ago for regenerative medicine, a new turn
has been taken in pluripotent cells research when, in 2006, Yamanaka’s group reported the reprogramming of fibroblasts to
pluripotent cells with the transfection of only four transcription factors. Since then many researchers have managed to
reprogram somatic cells from diverse origins into pluripotent cells, though the cellular and genetic consequences of
reprogramming remain largely unknown. Furthermore, it is still unclear whether induced pluripotent stem cells (iPSCs) are
truly functionally equivalent to embryonic stem cells (ESCs) and if they demonstrate the same differentiation potential as
ESCs. There are a large number of reprogramming experiments published so far encompassing genome-wide
transcriptional profiling of the cells of origin, the iPSCs and ESCs, which are used as standards of pluripotent cells and
allow us to provide here an in-depth analysis of transcriptional profiles of human and mouse cells before and after
reprogramming. When compared to ESCs, iPSCs, as expected, share a common pluripotency/self-renewal network. Perhaps
more importantly, they also show differences in the expression of some genes. We concentrated our efforts on the study of
bivalent domain-containing genes (in ESCs) which are not expressed in ESCs, as they are supposedly important for
differentiation and should possess a poised status in pluripotent cells, i.e. be ready to but not yet be expressed. We studied
each iPSC line separately to estimate the quality of the reprogramming and saw a correlation of the lowest number of such
genes expressed in each respective iPSC line with the stringency of the pluripotency test achieved by the line. We propose
that the study of expression of bivalent domain-containing genes, which are normally silenced in ESCs, gives a valuable
indication of the quality of the iPSC line, and could be used to select the best iPSC lines out of a large number of lines
generated in each reprogramming experiment.
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Introduction
Since Yamanaka’s groupshowed in 2006 that mouse somatic cells
could be brought to a pluripotent state by transfection of only four
transcription factors (Pou5f1 (Oct4), Sox2, Klf4 and c-Myc) [1] the
iPSC field has generated a great deal of enthusiasm, leading to the
achievement of significant advances in a relatively short period of
time (see Figure 1 for a graphical overview of experiments published
between 2006 and August 2009 and supplementary File S1 for a
more detailed and updated list and references). Briefly, cornerstone
publicationsinthereprogrammingfieldhavedescribed thefollowing
attributes of iPSCs: they can be transmitted to the germ line [2],
generated without the oncogenic factor c-Myc [3,4], obtained
from human cells using the same set of factors [5,6] as well as other
factors [7], obtained without permanent genomic manipulation
[8,9,10,11,12,13], produced from patient cells [14,15,16] even with
the correction of a genetic disease [17], and more recently, a study
demonstrated that iPSCs can give rise to viable mice by tetraploid
complementation assays [18,19,20]. Similar to ESCs, iPSC lines
have been shown to differentiate into derivatives of the three
embryonicgermlayers.Morespecifically,studieshavedemonstrated
iPSC’s ability to generate cells of the cardiovascular and hemato-
poietic lineages [21,22], insulin-secreting islet like structures [23],
functional cardiomyocytes [24], cells of the neural lineages [25], cells
of the adipose lineage [26] and retinal cells [27]. Moreover, a
number of papers have began to decipher the mechanisms involved
in reprogramming [28,29,30,31,32,33,34,35,36], a phenomenon
that will likely require significant effort in order to be fully
understood.
Starting from a small biopsy of skin or even a single hair [37],
cells are now routinely obtained that possess the same properties of
self-renewal and pluripotency as ESCs, but overcome the ethical
issues related to the use of embryos to derive ESCs. Thus, iPSCs
could replace ESCs and represent an invaluable tool for
regenerative medicine, as well as for the study of basic biological
processes, improved understanding of diseases, and finally, as a
tool for facilitating drug testing [38]. More importantly, patient-
specific iPSCs could potentially be used for the same range of
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12664Figure 1. Timeline of publications in the reprogramming field. Timeline of publication of reprogramming papers in mouse and human, with
a simplified classification of the main message/achievement of each paper. See supplementary File S1 for a more detailed and updated description of
published reprogramming reports.
doi:10.1371/journal.pone.0012664.g001
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overcoming the rejection risk after transplantation. However, the
replacement of ESCs with iPSCs for all these applications
presumes that they are as potent as ESCs in regards to their
differentiation potential and most importantly, that they are at
least equally safe for future clinical applications.
A significant part of the research dedicated to iPSCs has thus far
focused on improving a largely inefficient and possibly unsafe
reprogramming process. Several factors are taken into account to
judge if a modification of the protocol brings about an
improvement for reprogramming: (a) the efficiency and timing of
colony appearance (b) the number and type (oncogene or not) of
factors used, which might depend on the delivery method, the
somatic cell type and the co-use of chemicals and (c) the absence of
permanent genomic manipulation. The standard characterization
of iPSC lines encompasses the verification of a rather large panel
of morphological, molecular and functional attributes (see [39] for
review), which is expensive and time consuming. While the
necessity of full characterization for each generated iPSC line is
still being debated, the number of cell lines being produced
increases exponentially [40,41]. Therefore, a simple screening
method to select the best reprogrammed lines for full character-
ization would be extremely useful.
The reprogramming efficiency provided by different methods,
defined as the number of bona fide iPSC colonies obtained per
starting cell, is relatively easy to estimate, whereas assessing the
quality of the generated cell lines remains approximate. While the
stringency of the pluripotency tests available for mouse, reaching
to the birth of mice from tetraploid complementation experiments
[18,19,20] seems convincing, pluripotency of human cells is far less
easy to prove. Indeed, the most solid pluripotency test available for
human iPSCs is their ability to form teratomas. However, a recent
study shows that human iPSCs lines that are not fully
reprogrammed are also able to form teratomas, suggesting that
this cannot be the ultimate test to judge the quality of human
iPSCs [42]. Additionally, as discussed in [43], it is possible to
define sub-states of pluripotency and ESCs seem to be a
heterogeneous population of cells with slightly dissimilar differen-
tiation potentials. ESCs would be able to move from one sub-state
to another to form a pluripotent population overall. We set out to
test whether iPSCs possess this same kind of plasticity and do not
show any obvious bias towards some lineage fate due to the
reprogramming process they went through or because of memory
of the germ layer they originate from.
Different comparisons of genome-wide transcriptional profiles
between ESC and iPSC lines have shown that they share a
common pluripotency network [44], but also have a distinct
expression signature [45]. These analyses however, were limited to
a few reprogramming experiments. Very recently, these latest
results have been challenged, showing that there is no distinct
signature conserved across reprogramming experiments (neither at
the gene-expression nor at the chromatin mark level for the marks
H3K4me3 and H3K27me3) [46], but rather a lab-specific
signature [47], or traces of cell memory [48,49]. Using a greater
number of published genome-wide transcriptional profiles of
iPSCs with somatic starting cell populations and ESCs in Human
and in Mouse. we highlighted similarities of iPSCs and ESCs
compared to the starting somatic populations to build networks of
genes consistently higher expressed in pluripotent stem cells and
therefore potentially important for the reprogramming process.
Although both ES and iPS cells are pluripotent, there still are some
subtle differences in gene expression which may prove functionally
relevant, as was shown for a locus in mouse cells [50]. Therefore
we also checked the differences between iPSCs and ESCs to reveal
potential functional disparities between these cells. In connection
to this, we propose to study the expression levels in iPSCs of genes
which are poised in ESCs: not or lowly expressed and marked by
bivalent domains[51]. In ESCs, bivalent marks, characterized by
the simultaneous presence of histone H3 trimethylation at lysine 4
(H3K4, a mark that usually correlates with transcriptional
activation) and lysine 27 (H3K27, a mark that usually correlates
with transcriptional repression), are thought to be associated with
developmental genes which are usually silenced in undifferentiated
cells but ready to be expressed upon differentiation and are
therefore likely to play an important role in the early stages of
differentiation [51] Their expression in pluripotent cells might hint
at a bias towards a restricted fate during differentiation of the iPSC
line, which could result in improper differentiation towards other
lineages. We consider this to be a screening test for well
reprogrammed iPSCs. In addition, in regards to the safety issues,
we checked the expression of oncogenes and tumor suppressor
genes differing in iPSCs from ESCs, and which could be the
source of higher risks.
Materials and Methods
Gene expression analysis
The datasets used for the human analyses are: Takahashi et al.
(GSE9561) [5]; Yu et al. (GSE9071) [7]; Park et al. (GSE9832) [6];
Zhao et al. (GSE12922) [52]; Masaki et al. (GSE9709) [33]
Maherali et al. (GSE12390) [30]; Aasen et al. (GSE12583) [37];
Huangfu et al. (pers. comm.) [53]; Lowry et al. (GSE9865) [54];
Ebert et al. (GSE13828) [15]; Yu et al. (GSE15148) [55]; Soldner
et al. (GSE14711) [11].
The datasets used for the mouse analyses are: Takahashi et al.
(GSE5259) [1]; Okita et al. (GSE7841) [2]; Maherali et al.
(GSE7815) [30]; Feng et al. (GSE13211) [56]; Sridharan et al.
(GSE14012) [35]; Wernig et al. (E-MEXP1037) [4]; Chen et al.
(GSE15267); Zhou et al. (GSE16062)[57]; Zhao et al.
(GSE16925)[20]; Kang et al. (GSE17004)[19]; Heng et al.
(GSE19023)[58]; Ichida et al. (GSE18286)[59]; Mikkelsen et al.
(GSE8024) [60]; Hong et al. (GSE13312)[61].
Datasets coming from analyses performed on an Affymetrix
platform have been renormalized using the GC-RMA algo-
rithm[62] implemented in the R software (http://www.r-project.
org/). Other datasets have been used as normalized by their
respective authors.
For each dataset, the analysis was performed as follows
(summarized in Figure S1): we have calculated a percentrank
(pr) for each probe in each sample and each replicate. A
percentrank is defined as the rank of a value in a dataset as a
percentage of the dataset. This function evaluates the relative
standing of a value within a data set. For microarray studies, it
means that the probe with the highest intensity will get the rank
100%, whereas the probe with the lowest intensity will get the rank
0%. We estimate that the lowest 40% ranks reflect noise (as all
genes of a genome are not expressed in a given cell, at a given
time, and under a given condition, and based on the fact that, in
ESC lines cultured in our institute, the number of presence calls by
the mas5call function is around 60% when studying gene
expression with the Affymetrix HGU-133 plus 2.0 platform).
Next, we have introduced a weighting factor for each probe. The
weight of each probe is defined as a log2 value of the intensity of
this probe in a given sample divided by the sum of log2 of all
probes in the sample. (As we used GC-RMA normalized data for
the Affymetrix platform, which are already logarithms, we skipped
this step for the Affymetrix data, and defined the weight as the
GC-RMA value divided by the sum of GC-RMA values on the
Transcriptome of iPSCs
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(wpr) for each probe in each sample and each replicate, defined as
the percentrank of this probe multiplied by its weight (wpr= pr
*weight). Next, the average percentrank and the average weighted
percentrank were identified for the replicates of each sample. In
addition, for the dataset GSE7841 we have averaged the available
iPSCs samples (day2, day16, day17 and day18). For the dataset E-
MEXP-1037 we have averaged iPSCs samples (clones 8 and 18).
For the dataset GSE13211 we have averaged MEF, iPSCs OSCE
(clones 8 and 13) and iPSCs OSE (clones T8 and T9) samples. For
the dataset GSE14012 we have averaged ESCs (v6.5 and E14),
MEFs (male and female) and iPSCs (1D4 and 2D4) samples. For
the dataset GSE15267 we have averaged ESCs (CGR8 and R1),
iPSCs reprogrammed with four factors (S2C12 and S2C16) and
iPSCs reprogrammed with 3 factors (S53C1 and S53C5). For the
dataset GSE19023 we have averaged MEFs (Actin-GFP and
Pou5f1-GFP) and N2SK (#3 and #11) samples. For the dataset
GSE18286 we have averaged ESCs samples.
We have considered probes that have average pr below 0.4 for
both ESCs and MEFs as not expressed in the experiment and have
excluded them from the analysis. We have calculated the absolute
difference in average wpr between ESCs and MEFs, and have
ordered the probes in descending order according to that
difference, so that the probes changing the most between ESCs
and MEFs got the highest rank. The same procedure was also
performed for the iPSCs and MEFs comparisons.
For our analysis we have decided to define a gene as a Unigene
cluster. Since in many cases there are several probes correspond-
ing to one Unigene ID, we have performed the following to keep
one probe per one Unigene ID: If there was one probe
corresponding to the Unigene ID, we have kept this probe for
the analysis. If there were several probes corresponding to the
Unigene ID, we have kept the probe with the highest rank in the
ordered list for the analysis, and discarded all other probes.
For each of the comparisons (ESCs vs somatic cells, iPSCs vs
somatic cells) we have selected the top 1,000 most highly ranked
Unigene clusters (see supplementary File S2 for Human), and have
separated them according to the gene expression change direction
(up- or downregulated). To identify genes most up- or downreg-
ulated in both ESCs and iPSCs vs. somatic cells, we have kept only
genes that are in the top 1,000 in at least 44% of available
comparisons (and at least in 2 comparisons) in both ESCs and
iPSCs vs. somatic cells.
In mouse, 346 genes are consistently upregulated in ESCs and
iPSCs vs MEFs, and 462 genes are consistently downregulated in
ESCs and iPSCs vs MEFs. In human, 338 and 340 Unigene
clusters, respectively, were expressed higher and lower in both
iPSCs and ESCs compared to fibroblasts or keratinocytes.
Principal component analysis for each experiment
The principal component analysis to highlight the grouping of
iPSCs and ESCs far from the starting cell type (with or without
overlap of iPSCs and ESCs) has been conducted in R using the
GC-RMA profiles of series matrix for non-Affy platforms using the
pcromp function. Graphs were made using the first two
components.
Genes whose promoter is bound by diverse transcription
factors in mouse ESCs
Data about the binding of nine transcription factors important
for pluripotency/self renewal and reprogramming in mouse
promoters of known genes (Nanog, Sox2, Dax1, Nac1, Pou5f1
(Oct4), Klf4, Zfp281, Rex1 and Myc) has been extracted from
[63].
Data about the binding of polycomb-complex genes Suz12 and
Eed in mouse ESCs has been extracted from [64]. For the mouse
network of upregulated genes, the supplementary File S3
summarizes their chromatin marks on H3K4 and H3K27 in
ESC and MEF, as well as transcription factors bound and the
percentage of comparisons in which they have been in the top
1000 changes.
Analysis of bivalent domain-containing genes in human
ESCs
In order to evaluate the expression of genes containing bivalent
domains, and thereby the quality of the reprogrammed iPSCs
compared to ESCs, we have used an overlapping set of genes from
3 genome-wide characterizations of bivalent domain containing
genes [65,66,67] which we consider a high confidence set, and
have only used the 316 Ensembl genes for which we had
expression values in each dataset tested (see Figure S2). We have
considered percentrank values for the comparison between iPSCs
and ESCs.
The correlation coefficient between different profiles (genome-
wide and for those 316 genes) was calculated using the correl
function in Excel (see Figure S3).
Functional analysis of upregulated and downregulated
genes
We have investigated the function of the up- or down-regulated
genes in ESCs and iPSCs vs somatic cells using DAVID [68].
Genes were organized according to biological process, molecular
function and cellular component based on the Gene Ontology
(GO) [69] annotations. In addition, we used the tool searching the
Kyoto Encyclopedia of Genes and Genomes (KEGG) [70]
database of biochemical pathways to identify pathways that are
upregulated in ESCs and iPSCs, or MEFs.
We have investigated possible functional associations among
upregulated and downregulated genes using STRING [71]. A
network of genes that were predicted with a high confidence
(STRING score 0.7 at least) as interacting partners were visualized
using MEDUSA [72].
Results and Discussion
iPSCs and ESCs exhibit a common pluripotency network
A large effort to characterize the transcriptome of pluripotent
cells has shown that a pluripotency network built from a large
number of stem cells (the ‘‘stem cell matrix’’) is also mostly shared
by iPSCs[44]. This analysis, mostly focused on embryonic and
adult stem cells, took into account only a couple of iPSC lines. To
gain a more thorough insight into the functional equivalence of
iPSCs and ESCs, we set out to analyze available datasets of
genome-wide gene expression profiles of starting cell types versus
reprogrammed cells (iPSCs) and ESCs. An important challenge
that we faced during our analysis was in regards to the variability
in gene expression that exists between different ESC lines [73]
which seemingly does not influence their pluripotency and self-
renewal capacities. Similarly, we expected iPSCs to show a certain
level of variability in gene expression between each other and even
more markedly than ESCs because they originate from different
cell types, have been obtained with different factor combinations
and delivery methods and their self renewal and pluripotency
qualities are not always fully proven. Reassuringly though,
performing a principal component analysis for each reprogram-
ming experiment available, we always saw that iPSCs are much
closer to ESCs than to the starting somatic cells, based on their
genome-wide transcriptional profile (see PCA analysis in Figure
Transcriptome of iPSCs
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was available, very rarely iPSC and ESC samples are mixed. In
most cases, iPSC samples cluster together away from ESC
samples. This suggests than in most reprogramming experiments,
although close to ESCs, iPSCs contain a gene-signature that could
differentiate them from ESCs in accordance to [45] or that iPSCs
and ESCs are not strictly equivalent on a transcriptome level.
Before investigating the differences between iPSCs and ESCs,
we concentrated on the most consistent similarities observed
between them to determine the genes and pathways that appear
important for pluripotency and self-renewal and that are activated
or silenced during reprogramming. 346 genes in mouse consis-
tently showed a higher expression in both iPSCs and ESCs
compared to fibroblasts and 462 genes consistently showed a lower
expression level in both iPSCs and ESCs as compared to
fibroblasts. In human cells, we obtained 338 and 357 Unigene
clusters that were expressed at higher or lower levels, respectively,
in both iPSCs and ESCs compared to the starting cell populations
(see supplementary File S2 for Human). These lists of genes were
extensively analyzed using protein-protein interactions data, gene
ontology (see Figure S5) and literature analysis to gain insight into
their functionality (see supplementary Text S1 for the functional
description of the genes up-and down- regulated in Mouse ESCs
and iPSCs compared to MEF).
Using the genes that are significantly upregulated in ESCs and
iPSCs, we have built, for both Human (Figure 2) and Mouse
(Figure 3), an interaction network that represents the core
pluripotency network and includes genes involved in developmen-
tal processes, stem cell maintenance and transcriptional regulation
(see DAVID GO analysis in Figure S5). Our network shows a
central and highly interconnected area, present both in the mouse
and human analysis, where we can identify common pluripotency
regulators, which are mainly transcription factors (Oct4, Sox2,
Nanog, Lin28, Sall4, Otx2, Zfp42, Zic3 and Nr6a1) and TGFb/
Figure 2. Human protein-protein interaction networks of genes with higher expression levels in ESCs and iPSCs compared to
somatic cells. The human protein-protein interaction networks of genes most consistently highly expressed in ESCs and iPSCs, compared to the
starting cell populations, have been created from the lists of the biggest changes in expression, using String[71] with high confidence interactions
(min score 0.7) and have been edited in Medusa[72]. They show a central, highly interconnected network of genes in which the most famous
pluripotency transcription factors are to be found and which is likely to represent the core pluripotency network. They also highlight a number of
genes whose functions relate to cell-cell communication, cell cycle, DNA repair and other metabolisms.
doi:10.1371/journal.pone.0012664.g002
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Interestingly, most of these genes are bound in ESCs by two or
more pluripotency and/or reprogramming factors and are mostly
not bound by the polycomb group (see Figure S6 and
supplementary File S3). Moreover, they possess high levels of
H3K4 trimethylation at their regulatory regions in ESCs
compared to fibroblasts (see Figure S6). While our network
includes several factors that have been used successfully for
reprogramming, it also includes other potential factors that might
contribute to this process and may warrant further investigation.
It is also worth noting that genes involved in different functions
and pathways are consistently more highly expressed in ESCs and
iPSCs than in fibroblasts, such as those related to tight junction
(Cldn4, Cldn7, Cdh1 and Jam2), amino acid (Gldc, Shmt1 and
Gsta4) and lipid (Apoc1 and Apoe) metabolism, chromatin
remodeling (Rcor2 and Hmgb2), DNA repair and stress (Brca1
and Gsta4), DNA methylation (Dnmt3b and Dnmt3l) and cell
cycle regulation (Mybl2 and Utf1). However, these ‘‘secondary’’
functions seem to be less tightly regulated, as is reflected by the
lower percentage of experiments in which these genes show higher
expression in ESCs and iPSCs compared to fibroblasts, among the
top 1,000 changes (see Figure S7).
Among the genes that show lower expression in ESCs and
iPSCs compared to fibroblasts, we see a number of fibroblast-
specific genes involved in extracellular matrix metabolism, cell
adhesion, cytoskeleton organization, signaling pathways and
differentiation related transcription factors both in mouse and
human (see supplementary information for a more specific
description). Overall, it seems consistent that the reprogramming
process involves the erasing of a somatic cell specific expression
program, and notably the silencing or at least repression of
differentiation genes.
We should mention at this point that although genome wide
transcriptional profiles give interesting clues about the events
taking place in reprogramming, which are necessary for the
acquisition and maintenance of pluripotency and self-renewal,
other regulatory biological processes such as epigenetics, alterna-
tive splicing, regulation by microRNAs, or post translational
modifications[74] will also have to be taken into account.
Disparities between ESCs and iPSCs are revealed from
their genome-wide transcriptional profiles
The first observation when comparing genome-wide transcrip-
tional profiles of iPSCs and ESCs is, as expected, the high
Figure 3. Mouse protein-protein interaction networks of genes with higher expression levels in ESCs and iPSCs compared to
somatic cells. The mouse protein-protein interaction networks of genes most consistently highly expressed in ES and iPSCs, compared to the
starting cell populations, have been created from the lists of biggest changes in expression, using String[71] with high confidence interactions (min
score 0.7) and have been edited in Medusa[72]. They show a central, highly interconnected network of genes in which the most famous pluripotency
transcription factors are to be found and which is likely to represent the core pluripotency network. They also highlight a number of genes whose
functions relate to cell-cell communication, cell cycle, DNA repair and other metabolisms.
doi:10.1371/journal.pone.0012664.g003
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coefficients usually above 0.9 (1.0 meaning identical, see Figure
S8). However, differences do exist between iPSCs and ESCs
transcriptional profiles and it is important to investigate whether
they are relevant to iPSC biology. At a first glance, we noted that
even within the core pluripotency network, not all genes were
expressed at the same levels in ESCs and iPSCs, or at least not
consistently in all experiments, as is highlighted in Figure S7 for
the mouse network. Interestingly, when factors among the core
pluripotency network show differences, they are usually expressed
at a lower level in iPSCs than in ESCs, suggesting that iPSCs did
not reach the full pluripotency-associated transcriptome. This has
been shown to some extent by Gosh et al. [48] and more recently
confirmed by Polo et al. [75].These differences, though sometimes
subtle, might have functional consequences, as shown for an
imprinted locus in mouse cells by Stadtfeld et al. [50]. For
example, within the pluripotency network the levels of factors such
as Oct4 or Sox2 have to be tightly regulated in order to maintain
the balance between self-renewal and differentiation. This
complex and tight regulation is also reflected by the large number
of transcription factors known to be involved in pluripotency and/
or self-renewal, occupying the promoters of the genes in this
central network in ESCs (see Figure S6).
In 2009, Chin et al. also concentrated on the differences
apparent between ESC and iPSC expression profiles and
proposed, after comparing four different reprogramming experi-
ments, that iPSCs are distinguishable from ESCs as they have a
discrete (and conserved among experiments) gene expression
signature usually reflecting insufficient induction of "ESC genes"
and suppression of "fibroblasts genes" [45]. However, no
functional pattern can be predicted from this signature nor can
the consequences of those differences. We reproduced this analysis
and extended it to more datasets, considering genes that show a
minimum fold change of 1.5 and pvalue of 0.05 as differentially
expressed between ESCs and iPSCs. In agreement with Chin et al,
we identified a number of genes oftentimes differentially expressed
between ESCs and iPSCs (see Figure S9). A majority of the genes
that are up-regulated in ESCs compared to fibroblasts (‘‘ESC
genes’’) are expressed lower in iPSCs than in ESCs. Accordingly, a
majority of the genes that are down-regulated in ESCs compared
to fibroblasts (‘‘fibroblasts genes’’) are higher expressed in iPSCs
than in ESCs. Indeed this expression pattern might suggest that
iPSCs are not fully reprogrammed and are keeping a memory of
the cell type of origin. This might disturb their self-renewal and/or
pluripotency competency if the level of these genes matters in
pluripotent cells. However, the number of common genes that are
differentially expressed in ESCs and iPSCs is reduced as more
datasets are overlapped (see Figure S10), and these genes are not
always consistently either lower or higher expressed among all
compared iPSCs and ESCs. Hence, the number of genes showing
a significant difference in gene expression between ESCs and
iPSCs in most tested comparisons is low. Similar conclusions have
been drawned very recently suggesting that the differences
observed between ESC and iPSC are not conserved, and rather
a reflection of a laboratory-bias (which may represent cell of
origin, cell culture, reprogramming method…) [46,47], although
Chin et al. could confirm their results and further suggest that the
type of reprogramming influences the extent of differences
between ES and iPS cells [76]. The differences between ES and
iPS cells we observe to not seem to be biased towards the cell type
of origin, but rather seem to represent a tolerance for the
expression of some somatic genes in pluripotent cells. Unfortu-
nately, the multiplicity of methods and hands used for repro-
gramming certainly contributes to blurring any systematic bias and
no definitive conclusion can be drawn concerning cell memory in
this setup. A more controlled experiment should give an indication
to whether a specific memory exists for the cell of origin. Such
experiments have started to be performed, which in fact do hint at
the existence of some cell memory [75].
Monitoring the expression level of bivalent domain-
containing genes could be used to screen for the best
reprogrammed iPSC lines
Although the differences in gene expression observed between
ESCs and iPSCs do not seem to be directly affecting self-renewal
or pluripotency, we hypothesized that they could affect the
differentiation potential of iPSCs, a property that has not been
exhaustively tested yet and will be a major concern for future
applications. In order to evaluate this hypothesis, we compared the
expression levels of bivalent-domain containing genes between
human ESCs and iPSCs. We would like to point out that we think
that the concept of cell memory and conserved differences in gene
expression between ES and iPS cells are important, and have been
addressed in a number of studies[45,46,47,75,76]. We believe
however that reprogramming may take different paths (which we
are not able to infer as we merely have snapshots of the starting
and end point) to achieve the pluripotent state, and hence leave
different "scars", which albeit not consistent may have functional
consequences. Therefore, we decided to focus on each individual
iPSC line for the analysis of bivalent genes. Hence, for each
human and mouse dataset we studied the expression of genes
carrying bivalent domains in ESCs that were obtained from the
overlap of three ChIP-on-chip studies in human [65,66,67] or in
mouse [60,65,77] (Figure S2). We examined the correlation
coefficients of the genome-wide transcriptional profiles of ESCs
and iPSCs and the profiles of genes marked with bivalent domains
(see Table 1 and Figure S3). Since the characterization of the
published iPSC lines are usually more thorough in mouse, we
decided to test our hypothesis on the mouse iPSC lines. Although
the correlation coefficients are generally high for genome-wide as
well as for the set of bivalent domain-contaning genes, we see some
striking differences among reprogramming experiments. It is
noteworthy that the bivalent genes profiles of the iPSC lines
described to contribute to viable mice through tetraploid
complementation assay (the most stringent proof of pluripotency
available so far, GSE16925 and GSE17004) have the highest
correlation coefficients when compared with the ESC lines. As
expected, the correlation between bivalent genes profiles of
fibroblasts and ESCs is very low and especially much lower than
the one obtained from the comparison of genome-wide profiles.
Moreover, the correlation between partially reprogrammed cells
[52,54], which can self-renew but have not reached pluripotency,
and ESCs is much lower when comparing the expression of genes
marked with bivalent domains, supporting the idea that this
correlation is a good indicator of the quality of the reprogrammed
cells. As mentioned earlier, bivalent domain marked genes are
usually silenced or expressed at low levels in ESCs. However, in
our analysis we found a number of the genes described to have
both H3K4 and H3K27 methylation marks in ESCs that are
significantly expressed in most ESC lines analyzed. This could
reflect the presence of a heterogeneous population of ESCs [43],
the presence of a number of differentiating or differentiated cells in
the ESC culture or that the coocurrence of other undescribed
chromatin marks at the regulatory regions of these genes renders
them transcriptionally active. Thus, in agreement with the model
of bivalent domain containing genes we rely on, we concentrated
on the bivalent domain containing genes that are silent in at least
80% of the mESC lines for which we had available microarray
Transcriptome of iPSCs
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PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12664data, and among them we identified those expressed in each
individual iPSC line as "potentially problematic genes" since their
silencing in a pluripotent cell population is supposedly required.
We believe that these genes are the ones whose expression in
iPSCs could restrict or at least bias the differentiation potential.
Encouragingly, the iPSC lines that were shown to generate viable
mice by tetraploid complementation assays (GSE16925 and
GSE17004) express none to very few of such genes, whereas the
first iPSCs generated that did not contribute to the germline
(GSE5259), as well as the partially reprogrammed iPSC lines
(GSE14012), express a number of these potentially troublesome
genes (Figure 4). For example, the partially reprogrammed iPSC
lines 1A2 and 1B3 (GSE14012), as well as the Fbx15KO iPSC
line, which showed a limited potency (GSE5259), express Hoxc8,
which is a homeodomain gene important for early embryogenesis,
especially for neural development, and whose expression level is
normally tightly regulated [78] and quasi-inexistent in the ESCs
used in our study. The expression of this developmental gene
might explain or at least reflect the limited potency of these lines.
We extracted a list of potentially problematic genes for human
based on similar criteria, and being a little bit more conservative,
i.e. only genes which are expressed in a maximum of 1 ESC line
present in our study (see supplementary File S4). The number of
"potentially problematic genes" for some of the human iPSC lines
is depicted in Figure S11. Interestingly, the two studies using
OCT4, SOX2, LIN28 and NANOG as the reprogramming
cocktail (from normal and SMA patient fibroblasts) show a
reduced number of "potentially problematic genes." A little bit
more concerning is the rather large number of "potentially
problematic genes" expressed in some of our KiPS lines, which
passed all standard criteria for pluripotency tests available in
human. This again raises the question of the possible lack of
stringency of pluripotency tests in human, and also highlights the
differences observed from 2 lines obtained in similar conditions,
and the fact that each line, to a certain extent, probably follows its
own path of reprogramming.
Although it has become increasingly clear that ESCs and iPSCs
exhibit differences, systematic biases are hard to highlight (and
thereby biological significance of the differences hard to assess).
This could also be explained by the fact that not only might ESCs
and iPSCs be at different pluripotent states, but that there is also
more than one iPSC state, and reprogramming can possibly take
different routes to achieve pluripotency and self-renewal [43]. This
unfortunately also means that each iPSC line which will be utilized
in further experiments, and especially for those for therapeutical
purposes, should be extensively characterized. We believe that
checking the silencing of "potentially problematic bivalent domain
genes," (i.e. the genes that have bivalent domains in ESCs and are
normally silenced in ESCs) in the generated iPSC lines can give a
good indication of the quality of each line, thus helping to select
the most promising iPSCs for further characterization.
Reprogramming barriers and safety of iPSCs
Tumorigenesis is currently one of the major concerns in the
pluripotent stem cells and regenerative medicine fields. The first
clinical trial using hESC-derived oligodendrocyte progenitor cells
for spinal cord injured patients has been stalled due to the
development of cysts in more than 50% of the patients [69].
Figure 4. Number of genes which may be problematic for further differentiation of mouse iPSC lines generated by different
laboratories. Number of bivalent domain-containing genes for each iPS cell line which show some expression in the iPS cell whereas they are silent
in 100% or at least 80% of available ESC lines analyzed, and therefore could influence the differentiation potential of the iPS cell lines.
doi:10.1371/journal.pone.0012664.g004
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PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12664Moreover, a recent report highlights that several mouse iPSC lines
displayed even higher rates of tumor formation when implanted
into recipient mice compared to ESCs [79]. It is likely that
understanding the molecular pathways controlling the transition to
pluripotency will uncover the potential risks which will affect the
clinical use of iPSCs and inspire strategies to overcome them.
Reprogramming must indeed circumvent the mechanisms that
normal adult somatic cells have developed to preserve cell identity,
ensure their functionality and protect them against viral infections,
cell damage and transformation. The first barrier that the cells face
during reprogramming consists of overcoming the initial stress
generated by the over-expression of transcription factors, which is
likely to activate mechanisms such as apoptosis, senescence and
decreased cell viability (see Figure 5). Interestingly, recent studies
identified the p53 pathway as a barrier against reprogramming
[52,61,80,81,82,83]. These observations raise the question of
whether rare cells that are deficient in this very important pathway
could be positively selected during the reprogramming process,
increasing the probability of accumulating mutations and genetic
aberrations, which would clearly increase their potential tumor-
igenesis risk.
Once the first barrier is passed, most of the cells end up trapped
in a partially reprogrammed state in which they have acquired
self-renewal capabilities and have, to some extent, down-regulated
the differentiation-specific transcription patterns, but yet have
failed to overcome the epigenetic barrier towards the activation of
the endogenous pluripotency genes and are thus non-pluripotent
[35]. Interestingly, these partially reprogrammed cells are very
similar to transformed cells in regards to their ability to grow
indefinitely in a relative undifferentiated state. Overcoming the
second reprogramming barrier leads to the reactivation of
endogenous pluripotency genes, which was hindered by the
presence of a repressive chromatin environment around their
regulatory regions. Activation of the endogenous pluripotency
network is likely to mediate the silencing of developmental genes
through the establishment of bivalent marks at the regulatory
regions of these genes. We suggest with our analysis of bivalent
domain-containing genes that their expression in iPSCs, implying
the aberrance or lack of establishment of epigenetic marks during
reprogramming, might give rise to cells with defective silencing of
some differentiation genes. In accordance with this proposal, a
recent report correlates the quality of human iPSC with the
acquirement of proper bivalent marks at differentiation genes [70].
Moreover, the genome wide analysis of DNA methylation at CpG
sites in ESC and iPSC indicates that at certain loci iPSCs remain
incompletely or aberrantly reprogrammed, and those are espe-
cially enriched at genes involved in developmental processes [71].
Thus, whenever the process of reprogramming-mediated silencing
fails, aberrant expression of developmental genes may occur,
affecting the differentiation potential of the cells. It could increase
the probability that cells cannot answer to the differentiation cues
supplied to them and that partially undifferentiated cells could
Figure 5. Barriers to reprogramming. The process of somatic cell reprogramming entails overcoming the cellular barriers that preserve cell
identity. The first barrier consists of the stress generated by the overexpression of factors that stimulates apoptosis and reduces cell viability. The p53
pathway is an important factor for this barrier. Many cells that overcome this barrier end up trapped in a partially reprogrammed state in which they
are able to self-renew but are not yet pluripotent, as reflected by their ability to form tumors when injected into immunosuppressed mice. These cells
are dependent on the presence of the transfactors and cannot activate the expression of the endogenous pluripotency factors due to the presence of
a non-permissive chromatin environment on their regulatory regions, constituting a second barrier to reprogramming. Only after overcoming this
barrier are cells fully pluripotent and able to produce teratomas after injection into immunodepressed mice.
doi:10.1371/journal.pone.0012664.g005
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PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12664remain after transplantation, which might be at the roots of
tumorigenesis that may impede potential future clinical applica-
tions [72].
In summary, it is possible that the process of reprogramming
promotes the positive selection of cells in which the mechanisms of
cell identity preservation are not fully functional either because
mutations or the establishment of aberrant epigenetic marks
during reprogramming confers on them a growth advantage
compared to the rest of the population. Either event could render
iPSCs more prone to tumorigenesis and/or show an aberrant
differentiation potential.
Hence, the origin and genetic and/or epigenetic history of the
cells used for reprogramming surely play a determining role in the
safety of iPSCs. The origin of the cells has already been shown by
Miura et al. to influence the risk of tumor formation [72]. This risk
seems to be dependent on the ability of the cells to differentiate,
and hence on the presence of a few remaining undifferentiated
cells in the transplant. Moreover, the in vitro manipulation and
expansion of cells is likely to cause stress and this should probably
also be taken into account. Following these guidelines, cord blood
stem cells, young and easily obtainable, may represent an ideal
candidate [78,79] when looking for the most suitable cell type to
start with.
In order to gauge more thoroughly the risks involved in the
possible usage of iPSC cells for therapy, we also compared the
expression levels of oncogenes and tumor suppressor genes
between iPSCs and ESCs and highlight in Figure S12 changes
that may render iPSCs at higher risk of tumorigenesis than ESCs.
Conclusions and outlook
After analyzing, in detail, genome-wide transcriptional profiles
of starting cell populations, partially reprogrammed cells and
iPSCs and comparing these with ESCs, we conclude that iPSCs
and ESCs share a well-defined core pluripotency network.
However, some core genes often seem expressed at lower levels
in iPSCs. In addition, this network comprises not only the usual
pluripotency transcription factors, but also genes not yet described
as, but likely to be, involved in pluripotency and/or self-renewal
and genes responsible for many other biological processes, such as
cell-cell communication and metabolism.
When analyzing the differentially expressed genes between
ESCs and iPSCs for each available experiment with human cells,
we see that differences are not systematic and most likely do not
reflect the memory of the cell type used for reprogramming.
Moreover, differences are found when comparing the expression
of critical developmental regulators (marked with bivalent domains
in ESCs), suggesting that the differentiation potential of iPSCs
could be different than that of ESCs.
Although we cannot answer the question of whether iPSCs are
truly functionally equivalent to ESCs, it seems increasingly obvious
that there exists more than one state of pluripotency. This would
explain why we can distinguish between ESCs and iPSCs, but also
between iPSCs generated with different protocols. As we believe it
is important to select the best iPSCs in terms of their
differentiation potential, we propose that checking the newly
generated iPSC lines for the silencing of a number of genes
marked with bivalent domains would assist in preselecting the
most promising iPSCs for further studies. Importantly, even
though the field of somatic cell reprogramming moves incredible
fast and brings us closer every day to getting the "perfect" protocol
for iPSC generation in terms of efficiency, a crucial question
remains: will we be able to get cells which are safe to use for
therapeutical applications? To answer this question, not only will
different cell types, ages and origins have to be tested, but also the
protocol used for the generation of the iPSCs. Moreover,
understanding the path through which somatic cells arrive to a
pluripotent state should allow us to evaluate, more accurately, the
potential risks inherent in the use of iPSCs in therapy. The
propensity of iPSCs to differentiate and not to go wayward after
transplantation, judged by the integrity of their genome and
epigenome, will need to be evaluated in great detail.
Supporting Information
Text S1 Detailed description of up and down mouse networks.
Functional description and relevance of genes present in the
networks of genes higher or lower expressed in pluripotent cells
than in MEFs.
Found at: doi:10.1371/journal.pone.0012664.s001 (0.31 MB
PDF)
Figure S1 Schematic representation of the strategy used to
reconstruct human and mouse networks of genes that are either
up-regulated or down-regulated in reprogramming.
Found at: doi:10.1371/journal.pone.0012664.s002 (0.23 MB
PDF)
Figure S2 In order to evaluate the expression of genes
containing bivalent domains, and thereby the quality of the
reprogrammed iPSCs compared to ESCs, we have used the
overlapping set of genes from 3 genome-wide characterizations of
bivalent domain containing genes (see figures below for the human
and mouse datasets) which we consider being a high confidence
set.
Found at: doi:10.1371/journal.pone.0012664.s003 (0.10 MB
PDF)
Figure S3 Correlation coefficients of different samples and
experiments on the profiles of 316 bivalent-domain-containing
genes in Human. It is important to note that the profile hasn’t
been always done on the same platform, which explains why the
correlation inter-experiments is sometimes not good.
Found at: doi:10.1371/journal.pone.0012664.s004 (0.14 MB
PDF)
Figure S4 Principal component analyses of Human and Mouse
reprogramming datasets show that ESCs and iPSCs usually cluster
together, far from the starting somatic cell population. Principal
component analysis of genome-wide intensity values (or log of
intensity gcrma-normalized) (A) Human datasets (B) Mouse
datasets.
Found at: doi:10.1371/journal.pone.0012664.s005 (0.72 MB
PDF)
Figure S5 Functional analysis of genes up- and downregulated
in Human and Mouse ESCs and iPSCs in comparison to somatic
cells using DAVID. Gene Ontology annotations of biological
process, molecular function and cellular component as well as
genes enrichment in KEGG pathways for the following compar-
isons: (A) genes upregulated in Human ESCs and iPSCs; (B) genes
downregulated in Human ESCs and iPSCs; (c) genes upregulated
in mouse ESCs and iPSCs; (d) genes downregulated in ESCs and
iPSCs.
Found at: doi:10.1371/journal.pone.0012664.s006 (0.21 MB
PDF)
Figure S6 Mouse network of genes upregulated in both ESCs
and iPSCs compared to MEF - Overlap with transcription factors
binding and chromatin marks in ESCs.
Found at: doi:10.1371/journal.pone.0012664.s007 (1.01 MB
PDF)
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expression change between MEF and iPSCs or ESCs within the
most significant changes in each studied dataset. Highlight of the
level of reproducibility of the presence of genes in the mouse
network of most significantly upregulated genes in ESCs and
iPSCs compared to MEF in all available comparisons between (A)
ESCs to MEF (B) iPSCs to MEF.
Found at: doi:10.1371/journal.pone.0012664.s008 (0.17 MB
PDF)
Figure S8 Analysis of the differences between ESCs and iPSCs
transcriptional profiles with a focus on bivalent-domain containing
genes in mouse and human datasets. Correlation coefficients for
genome-wide profiles and profile of genes containing bivalent
domains in ESCs for (A) Human (B) Mouse.
Found at: doi:10.1371/journal.pone.0012664.s009 (0.16 MB
PDF)
Figure S9 Overlap of genes showing significantly different levels
between iPSCs and ESCs in each dataset for Human and Mouse
with the direction of the change. The expression change direction
between fibroblasts and ES cells for genes which show differences
between ES and iPS cells confirms that a majority of genes
differently expressed between ES and iPS cells are "ES genes"
which are lower expressed in iPS than in ES cells. Blue columns
represent genes whose expression level is lower in ES cells than in
fibroblasts, while red columns represent genes whose expression
level is higher in ES cells than in fibroblasts.
Found at: doi:10.1371/journal.pone.0012664.s010 (0.18 MB
PDF)
Figure S10 Gene expression signature of iPSCs: reanalysis of
human and mouse datasets with the Chin et al. method. The
genome-wide gene expression profiles of iPSC and ESC lines were
compared for human (in total 8 pairwise comparisons) and mouse
(in total 15 pairwise comparisons). Genes showing a minimum fold
change of 1.5 and pvalue lower than 0.05 were identified as
significantly differently expressed between ESCs and iPSCs. The
number of comparisons of human (or mouse) iPSCs and ESCs is
represented on the X axes. The number of genes that are
differently expressed between human (or mouse) iPSCs and ESCs
in at least one comparison, as well as the overlap of two (or more)
comparisons, is represented on the Y axis.
Found at: doi:10.1371/journal.pone.0012664.s011 (0.09 MB
PDF)
Figure S11 Number of potentially problematic bivalent domain-
containing genes expressed in different human iPSC lines. The
iPSCs (different lines, different clones or different passages of the
same line) from the available human datasets are represented on
the X axis. For each iPSC, the number of bivalent domain-
containing genes expressed in the given iPSC whereas silent in
100% (blue) or in at least 90% (red) of the human ESC lines
analyzed, is represented on the Y axes.
Found at: doi:10.1371/journal.pone.0012664.s012 (0.20 MB
PDF)
Figure S12 List of tumor suppressor genes down-regulated and
oncogenes upregulated in human iPSCs compared to ESCs. List of
tumor suppressor genes and oncogenes whose expression levels
renders iPSCs suspicious.
Found at: doi:10.1371/journal.pone.0012664.s013 (0.04 MB
PDF)
File S1 Paper list. List of papers reporting reprogramming
experiments from human and mouse cells with their citation and
summarized message.
Found at: doi:10.1371/journal.pone.0012664.s014 (0.10 MB
XLS)
File S2 Top 1000 changes human. Summary of genes among
the top 1000 changes in any human pairwise comparison with
details of presence among the top 1000 and rank in all
comparisons and highlighting similarities and differences between
ES and iPS cells.
Found at: doi:10.1371/journal.pone.0012664.s015 (2.74 MB
XLS)
File S3 Summary genes in up network mouse. Summary of the
genes present in the network of genes higher expressed in
pluripotent cells than in MEFs, with annotation for chromatin
marks (H3K4me3 and H3K27me3) in MEFs and ESCs, as well as
binding by an array of transcription factors, among which the
usual reprogramming factors.
Found at: doi:10.1371/journal.pone.0012664.s016 (0.08 MB
XLS)
File S4 Potentially problematic genes. Summary of genes
marked with bivalent domains in ESCs, which are normally
silenced in ESCs and expressed in at least one iPSC line for human
and mouse, annotated with their phenotype in mouse, and for
which the expression level (as percentrank) is shown when higher
than 40% (considered actively expressed).
Found at: doi:10.1371/journal.pone.0012664.s017 (0.34 MB
XLS)
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